Abstract
Background Italy is bearing the brunt of the COVID-19 pandemic, as the death toll there has already surpassed that in Wuhan, the city in China where the coronavirus emerged in December 2019. Here we employ statistical methods to assess the severity of COVID-19 pandemic across different regions of Italy.
Method We manually retrieved the daily cumulative numbers of laboratory-confirmed cases and deaths attributed to COVID-19 stratified by region in Italy from March 2, 2020 to March 28, 2020. We estimated both the crude and time-delay adjusted case fatality ratio across five geographic regions of Italy: Northwest, Northeast, Center, South and Island.
Result The Northwest that includes Lombardy exhibited the highest time-delay-adjusted CFR at 31.4%% [95% credible interval: 30.8, 32.1%] followed by the Northeast (20.3%) [95% CrI: 19.4, 21.1], the Center region (16.5%) [95% CrI: 15.4, 17.7] and the South region (16.8%) [95% CrI: 15.0, 18.7]. The Island region has exhibited the lowest CFR (11.8%) [95% CrI: 9.0, 14.8].
Conclusion Italy is experiencing one of the highest CFR from the COVID-19 pandemic in the world. Time delay adjusted CFR in all the regions in Italy except the Island region were higher than that estimated for Wuhan, China. The CFR in Northwest Italy is 2.5-fold higher than that in Wuhan. Our finding reflects the need of urgent medical support in the Northwest region and the appropriate planning and supplies procurement in other regions of Italy with focus on medical care delivery to those who are at the highest risk of poorer outcomes due to COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
KM acknowledges support from the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 15K20936, from Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers Grant Number G2801 and from the Leading Initiative for Excellent Young Researchers from the Ministry of Education, Culture, Sport, Science & Technology of Japan. GC acknowledges support from NSF grant 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program; UK Biotechnology and Biological Sciences Research Council grant BB/M008894/1.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, KM, upon reasonable request.
